A high level of miR-200a/-183 indicates a low level of UGT1A9, thus reducing the formation of sorafenib β-D-glucuronic acid in HCC and reducing the efficacy of drugs. This evidence concerns the gene UGT1A9 and hepatocellular carcinoma.